Medical Research

AMRA’s MRI-based biomarkers, including proprietary z-scores, offer a groundbreaking solution, providing researchers with a unique understanding of the nature and impact of these changes. By precisely measuring muscle volume and fat infiltration (an indicator of muscle quality), AMRA’s technology uncovers the hidden dynamics of weight loss, empowering the development of more effective therapies.

The recent study details the use of fat-referenced volumetric muscle composition measurements as reliable biomarkers of disease progression and treatment response in sporadic inclusion body myositis, building upon AMRA’s increasing expertise in the neuromuscular disease space

The newly MDR-certified, next-generation AMRA® Profiler 4 device, a unique approach for quantifying fat and muscles, was evaluated in the study to be helpful in liver disease research, representing a crucial step forward for the use of muscle composition assessments in the field

The recent study – part of the CoMorMent initiative – provides new evidence for body composition measurements as an important tool for examining adverse treatment effects associated with the use of antidepressants

The recently published primer summarizes contemporary evidence indicating that muscle composition changes associated with GLP-1-based therapies appear to be adaptive

Researchers from AMRA will present an abstract at the 60th annual European Association for the Study of Diabetes Meeting that emphasizes the link between adverse muscle composition and all-cause mortality in Type II Diabetes